Where Regulatory Precision Meets Operational Integrity
Partnering with pharmaceutical organizations to navigate complex compliance landscapes, reduce regulatory risk, and sustain quality excellence across every stage of the product lifecycle.
A Trusted Counsel for Pharmaceutical Quality and Compliance
ReguQual Partners is a specialized pharmaceutical compliance consulting firm dedicated to helping drug manufacturers, clinical sponsors, and life sciences organizations meet and sustain the rigorous standards set by the U.S. Food and Drug Administration, European Medicines Agency, and global regulatory authorities.
The firm was founded by Dr. Tamer Helmy after repeatedly witnessing a critical gap in the industry—organizations struggling to translate regulatory expectations into practical, sustainable operations, particularly in the aftermath of FDA inspections. Too often, companies receiving a Form 483 or Warning Letter find themselves reacting under pressure, navigating ambiguity, and addressing symptoms rather than root causes. This recurring frustration—marked by unclear remediation paths, strained internal resources, and heightened regulatory risk—highlighted a deeper need for a partner who could bridge compliance requirements with real-world execution.
ReguQual Partners was built to meet that need. Our foundation rests on a clear conviction: effective compliance is not just about interpreting regulations—it’s about operationalizing them in a way that withstands scrutiny and drives long-term performance. We bring both regulatory authority and operational credibility, with deep subject matter expertise across the full spectrum of pharmaceutical quality—from facility design and contamination control to regulatory submissions, inspection readiness, and post-inspection remediation.
We identify and prioritize compliance gaps using a systematic, risk-based methodology aligned with ICH Q9 and current regulatory expectations.
Independent Audit Expertise
Our auditors maintain complete independence, providing objective assessments free from operational bias or commercial conflict of interest.
Documented, Defensible Deliverables
Every engagement produces audit-ready documentation structured to withstand regulatory scrutiny and inform corrective action planning.
Core Services
A Structured Framework for Pharmaceutical Compliance
01
Regulatory Compliance & Auditing
Comprehensive audit services against FDA and EMA standards, including pre-inspection assessments, supplier qualification audits, and 483 response support.
Learn More
02
GMP / GCP Compliance Programs
Gap analysis and remediation planning across Good Clinical and Good Manufacturing Practice requirements, tailored to your product type and applicable regulations.
Learn More
03
Quality Management System Development
Design, implementation, and optimization of QMS frameworks aligned with ICH Q10, ISO standards, and current FDA quality system expectations.
Learn More
04
Contamination Control Strategy
Develop, document, and implement risk-based, compliant strategies to manage microbial and particle risks, particularly focusing on EU GMP Annex 1 compliance. Offerings include gap analysis, risk assessment, facility design review, and staff training.
Learn More
Speak with a Specialist
Ready to Strengthen Your Compliance Position?
Our consultants are available to assess your current regulatory standing and identify priority areas for action.
Each engagement is structured to address the specific regulatory requirements, operational context, and risk profile of your organization.
Service 01
Regulatory Compliance & Auditing
FDA 21 CFR Part 10 / 11ICH Q9 & Q10Pre-inspection
Applies to pharmaceutical manufacturers, contract manufacturers, API suppliers, and clinical sites subject to FDA or EMA oversight.
ReguQual Partners conducts independent compliance audits calibrated to the current enforcement priorities and inspection standards of the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Our audit methodology is aligned with FDA's Systems-Based Inspection approach, the EU's Joint Audit Programme, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) guidelines.
Audits encompass facility systems, batch record review, deviation and CAPA management, laboratory controls, supplier qualification, and data integrity practices. Each audit produces a detailed finding report with risk-ranked observations, root cause analysis, and actionable remediation timelines.
We also provide Form FDA 483 observation response support, warning letter remediation consulting, and pre-approval inspection (PAI) readiness assessments for organizations preparing for FDA site visits.
Typical Deliverables
Audit report with risk-ranked findings (Critical / Major / Minor)
Root cause analysis and CAPA recommendations
Regulatory gap assessment summary
FDA 483 response drafting and review
Pre-inspection readiness briefing and mock inspection
Supplier qualification audit reports
Service 02
Current Good Manufacturing Practices
GMPICH Guidelines
Applicable to clinical trial sponsors, CROs, investigational sites, and commercial manufacturing operations.
Adherence to Current ood Manufacturing Practice (CGMP) is foundational to regulatory approval and continued market authorization. ReguQual Partners provides structured gap assessments, remediation planning, and ongoing compliance support against ICH E6(R2), ICH Q7, and the applicable 21 CFR requirements for clinical and commercial manufacturing.
Our GCP services address clinical trial design integrity, investigator site compliance, informed consent processes, data management practices, and monitoring oversight. GMP services cover manufacturing process controls, equipment qualification, cleaning validation, environmental monitoring, and batch release procedures.
Typical Deliverables
GMP / GCP compliance gap assessment report
SOP review and revision recommendations
Process validation protocol development support
Staff training program design and delivery
Clinical site qualification audit reports
Ongoing compliance monitoring schedule
Service 03
Quality Management System Development
ICH Q10eQMSQRM
Relevant to organizations building, expanding, or remediating their pharmaceutical quality management infrastructure.
A well-designed Quality Management System is the structural backbone of sustained pharmaceutical compliance. ReguQual Partners assists organizations in designing or remediating QMS frameworks that meet the requirements of ICH Q10, FDA's Quality System Regulation, and applicable ISO standards.
Our QMS engagements begin with a comprehensive assessment of existing quality infrastructure—document control, change control, deviation management, CAPA, management review, internal audit, and supplier oversight—against current regulatory standards and industry benchmarks. We provide recommendations for structural improvement and directly support implementation activities including SOP development, electronic QMS configuration, training curricula, and performance metric frameworks.
Typical Deliverables
QMS current-state assessment with gap matrix
Quality system architecture design documentation
SOP library development or remediation
eQMS selection support and configuration guidance
Management review framework and quality metrics dashboard
Internal audit program design
Service 04
Contamination Control Strategy
EU GMP Annex 1Microbial Control
Critical for sterile manufacturing facilities, aseptic processing operations, and organizations subject to EU GMP Annex 1 requirements.
The revised EU GMP Annex 1 (2022) imposes a comprehensive Contamination Control Strategy (CCS) requirement on manufacturers of sterile medicinal products. ReguQual Partners provides end-to-end support for developing, documenting, and implementing risk-based, compliant strategies to manage microbial and particle risks across your manufacturing environment.
Our CCS engagements are grounded in current regulatory expectations from the EMA, PIC/S, and the FDA's sterile drug manufacturing guidance. We conduct facility walk-throughs, environmental monitoring data reviews, HVAC and cleanroom qualification assessments, and personnel flow analysis to identify contamination risk pathways and evaluate existing control measures against the Annex 1 framework.
All deliverables are structured to serve as living documents within your quality system—reviewable, revisable, and defensible in the context of regulatory inspection or internal audit.
Typical Deliverables
Contamination Control Strategy document (CCS master file)
EU GMP Annex 1 gap analysis report
Microbial and particle risk assessment
Facility design and cleanroom classification review
Environmental monitoring program assessment
Staff training program on contamination control principles
Begin Your Engagement
Discuss Your Compliance Requirements
Each engagement is scoped individually to address your organization's specific regulatory context and objectives.
Founded on Deep Industry Experience and an Unwavering Commitment to Quality
Our firm is founded by Tamer Helmy, PhD, after spending years helping companies in the Pharma and Biotech industry meet their compliance needs. ReguQual Partners was built to deliver the kind of expert, independent counsel that turns regulatory complexity into competitive confidence.
"Compliance is not a destination. It is a discipline—one that demands consistent rigor, honest assessment, and the courage to identify what needs to change."
ReguQual Partners was established to address a persistent gap in pharmaceutical compliance consulting: the tendency to deliver technically correct but operationally impractical recommendations. Dr. Helmy recognized that sustainable compliance requires integration with the realities of manufacturing, clinical operations, and organizational culture—not just regulatory citation.
We maintain strict independence from the organizations we serve. Our consultants carry no financial or structural relationship with pharmaceutical manufacturers, contract organizations, or technology vendors, ensuring that every recommendation reflects the regulatory and quality interests of our clients.
Our engagements are grounded in current regulatory guidance, published inspection observations, and direct experience with the evolving enforcement posture of FDA, EMA, and other global health authorities.
Our Leadership
Expertise Across Every Domain of Pharmaceutical Compliance
Tamer Helmy, PhD
Founder & Principal Consultant
Dr. Tamer Helmy is a seasoned pharmaceutical quality and regulatory compliance leader with extensive experience guiding organizations across the pharmaceutical and biotechnology industries through complex compliance challenges. His career spans senior quality and regulatory roles at global pharmaceutical manufacturers, where he developed a reputation for building robust quality management systems, leading successful regulatory inspections, and driving sustainable compliance programs from the ground up.
Dr. Helmy's expertise encompasses GxP compliance, Quality Management System development, regulatory auditing, contamination control strategy, and the strategic application of risk-based quality principles aligned with ICH Q9 and Q10. He has worked with organizations at every stage—from early-stage biotech companies navigating their first regulatory submissions to established manufacturers preparing for FDA and EMA inspection.
His approach is defined by a commitment to practical, operationally grounded solutions: compliance programs that are not only defensible under regulatory scrutiny but sustainable within the day-to-day realities of pharmaceutical manufacturing and clinical operations. Dr. Helmy founded ReguQual Partners to bring that philosophy—and decades of hands-on expertise—directly to the organizations that need it most.
Inquiries are handled directly by a senior consultant. We respond to all initial inquiries within one business day and provide a preliminary scoping discussion at no charge.
Submit an Inquiry
Professional Disclaimer
Consulting services provided by ReguQual Partners are tailored to the specific regulatory requirements, operational context, and compliance obligations of each client organization. Information shared on this website is provided for general informational purposes only and does not constitute legal advice, regulatory guidance, or a guarantee of regulatory outcome. All engagements are governed by a mutually executed consulting services agreement that defines the scope, deliverables, and limitations of the services provided. ReguQual Partners is an independent consulting firm and is not affiliated with, endorsed by, or acting on behalf of the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other regulatory authority.
General Inquiries
info@reguqual.com (Engagements conducted nationwide and internationally)
Office Hours
Monday – Friday: 8:00 AM – 5:00 PM CST
For urgent regulatory matters (active inspections, 483 responses with imminent deadlines), please indicate the urgency in your submission or contact us directly by phone.
Confidentiality
All inquiries are treated as confidential. We do not share information provided in initial consultations with third parties. Formal engagements are covered by a mutual non-disclosure agreement executed prior to the exchange of sensitive organizational information.
Insights, interviews, and publications from Dr. Tamer Helmy and the ReguQual Partners team on pharmaceutical compliance, quality culture, and regulatory strategy.
Video Content
YouTube Channel
Watch Dr. Tamer Helmy discuss pharmaceutical compliance, quality systems, and regulatory strategy.
Tamer Helmy – ReguQual – Pharma Compliance
Expert commentary on pharmaceutical quality, GMP compliance, inspection readiness, and quality culture.
Pharmaceutical compliance insights from Dr. Tamer Helmy
About the Channel
Dr. Tamer Helmy shares expert perspectives on pharmaceutical compliance, GMP best practices, quality culture, and regulatory strategy for life sciences organizations.
Topics span FDA and EMA inspection readiness, quality management systems, contamination control, and building compliance programs in emerging biotech environments.
Dr. Tamer Helmy has contributed to leading pharmaceutical industry publications, addressing quality culture, compliance strategy, and workforce development in pharma and biotech.
